Welcome to our dedicated page for Swk Hldgs news (Ticker: SWKH), a resource for investors and traders seeking the latest updates and insights on Swk Hldgs stock.
SWK Holdings Corporation (Nasdaq: SWKH) is a life science focused specialty finance company that regularly reports on its financial performance, portfolio activity, and strategic transactions. As a provider of non-dilutive financing to small- and mid-sized commercial-stage healthcare companies, SWK’s news flow centers on its finance receivables portfolio, royalty monetization activity, and developments within its pharmaceutical development services operations.
Readers of this SWKH news page can expect updates on quarterly and annual financial results, including GAAP net income, segment-level non-GAAP metrics, effective yields on finance receivables, and changes in book value and tangible finance book value per share. The company frequently issues press releases in connection with its earnings reports and hosts conference calls to discuss its corporate and financial results.
SWK’s news also highlights portfolio transactions such as new term loans, expansions of existing credit facilities, sales and monetizations of royalty portfolios, and resolutions of nonaccrual positions or workout situations. Announcements have included the monetization of royalty assets, special dividends funded by those monetizations, and updates on loan payoffs and recoveries.
In addition, the company discloses strategic and corporate events, including its Agreement and Plan of Merger with Runway Growth Finance Corp., as well as updates on its pharmaceutical development subsidiaries. Investors following SWKH news gain insight into how SWK manages its life science finance portfolio, how non-GAAP measures relate to reported results, and how strategic transactions may affect stockholders. For those tracking the specialty finance and healthcare capital markets, this page offers a focused stream of company-issued information and regulatory news related to SWK Holdings Corporation.
Enteris BioPharma, a subsidiary of SWK Holdings Corporation (Nasdaq: SWKH), announced an accepted abstract for oral presentation at the ASRM 2022 Scientific Congress & Expo from Oct 22-26, 2022, in Anaheim, CA. The abstract focuses on pharmacokinetics of an oral formulation of leuprolide developed using Enteris' Peptelligence® platform, showcasing its efficacy in delivering superior drug levels compared to injectable products. The presentation is set for Oct 26, 2022, at 11:05 AM PT, highlighting advancements in oral administration for better patient compliance, particularly for diseases influenced by GnRH agonists.
Summary not available.
SWK Holdings Corporation (Nasdaq: SWKH) has been added to the Russell 2000, Russell 3000, and Russell MicroCap Indexes, effective June 27, 2022. This inclusion reflects the company's growth and aims to enhance shareholder value by increasing stock liquidity and awareness within the investment community. CEO Winston Black stated that the company is addressing funding needs in the life sciences sector while maintaining financial discipline. FTSE Russell, the index provider, ranks stocks based on market capitalization, and SWK's membership will last for one year, impacting future investment strategies.
Enteris BioPharma, a subsidiary of SWK Holdings (SWKH), presented two clinical studies on oral formulations of leuprolide at ENDO 2022. Results indicate that their Peptelligence® platform delivers significant circulating drug concentrations comparable to injected formulations. The studies demonstrated successful systemic delivery of leuprolide orally, with positive pharmacokinetic profiles and effective hormonal suppression of LH, FSH, and estradiol. No severe adverse events were reported, marking a milestone in alternative treatments for conditions like endometriosis.
Enteris BioPharma, a subsidiary of SWK Holdings (Nasdaq: SWKH), has published a white paper titled "Protecting Workers and the Environment: Facilities and Processes Key to Making Highly Potent Drug Products." The paper highlights the importance of specialized knowledge and facilities in manufacturing highly potent active pharmaceutical ingredients (HPAPIs). The recent renovation of Enteris' Boonton, NJ facility enhances its capabilities in HPAPI handling. Given the current shortage of U.S.-based facilities for HPAPI production, Enteris aims to address industry challenges through its advanced manufacturing capabilities.
On May 26, 2022, Enteris BioPharma engaged its employees in a charitable event, creating stuffed teddy bears for Ronald McDonald House Charities to comfort sick children. This initiative emphasized teamwork and community support, aligning with the company’s patient-focused values. The bears were distributed to families in New Brunswick, NJ, providing comfort during tough times. Enteris is a subsidiary of SWK Holdings Corporation (Nasdaq: SWKH) offering contract development and manufacturing services, leveraging proprietary drug delivery technologies to address unmet clinical needs.
SWK Holdings Corporation (Nasdaq: SWKH) announced a $200 million universal shelf registration statement on Form S-3 and a $10 million stock repurchase program authorized by its Board of Directors. The repurchase will be executed through a 10b5-1 trading plan until May 15, 2023. CEO Winston Black stated that these moves aim to enhance the company's financial position and support life sciences firms' capital needs. There are no guarantees regarding the completion of any debt offerings or the exact number of shares repurchased.
Summary not available.
SWK Holdings Corporation (SWKH) reported a strong first quarter of 2022 with total revenue increasing by 18% to $11.1 million year-over-year. The company achieved a GAAP net income of $3.5 million, reflecting a 2.9% growth. The finance portfolio realized yield rose to 22.5%, indicating solid loan performance. As of March 31, 2022, tangible financing book value per share reached $18.39, a 12.7% year-over-year increase. Total investment assets decreased by 10.6% year-over-year to $195.8 million. The company is well-positioned with $63.4 million available in cash and credit facilities.
SWK Holdings Corporation (Nasdaq: SWKH) will host a conference call and audio webcast on May 11, 2022 at 10:00 a.m. ET to discuss its Q1 2022 financial results. Participants can join by dialing (844) 378-6488 for the U.S. or (412) 317-1079 for international calls, using passcode 10166330. The webcast will be available on the company's website and archived for 90 days afterward. SWK specializes in financing solutions for small to mid-sized healthcare companies and owns Enteris BioPharma, which develops innovative drug delivery technologies.
FAQ
What is the current stock price of Swk Hldgs (SWKH)?
What is the market cap of Swk Hldgs (SWKH)?
